Welwyn Garden City, United Kingdom

Frank R Atherton


Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 67(Granted Patents)


Location History:

  • Welwyn Garden City, EN (1977)
  • Welwyn Garden City, GB (1978 - 1981)

Company Filing History:


Years Active: 1977-1981

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Frank R. Atherton: Innovator in Antibacterial Compounds

Introduction

Frank R. Atherton is a notable inventor based in Welwyn Garden City, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antibacterial agents. With a total of 7 patents to his name, Atherton's work has had a considerable impact on the pharmaceutical industry.

Latest Patents

Among his latest patents, Atherton has developed acyl derivatives that include peptide derivatives. These compounds are characterized by a general formula where R¹ can represent a hydrogen atom or various alkyl groups. The compounds exhibit activity as antibacterial agents against a range of gram-positive and gram-negative bacteria. Additionally, he has worked on halo-phosphonopeptides, which are also recognized for their antibacterial properties and their ability to enhance the effectiveness of antibiotics.

Career Highlights

Frank R. Atherton is currently associated with Hoffmann-La Roche Inc., a leading global healthcare company. His innovative work in the field of antibacterial agents has positioned him as a key figure in pharmaceutical research and development. Atherton's contributions are vital in the ongoing battle against bacterial infections.

Collaborations

Throughout his career, Atherton has collaborated with esteemed colleagues, including Michael J. Hall and Cedric H. Hassall. These partnerships have fostered a collaborative environment that enhances the research and development of new medicinal compounds.

Conclusion

Frank R. Atherton's innovative work in the field of antibacterial compounds has made a significant impact on medicine. His contributions continue to advance the development of effective treatments against bacterial infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…